TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01923948

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: One 150 mg oral dose of Pregabalin given before surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Pregabalin)
Description: One oral dose of placebo given before surgery
Study: NCT01887041

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stent
Description: Endoscopically inserted biliary tract drainage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biliodigestive anastomosis
Description: Biliodigestive anastomosis
Study: NCT00004192

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study: NCT02566525

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CytoSorb
Description: Cytosorb device use during cardiopulmonary bypass
Study: NCT00004192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Study: NCT02952950

Intervention type: OTHER
Group type: OTHER
Intervention: Oralstimulation
Description: The intervention group granted in total 1 hour instructions in a program of oral stimulation by one of two occupational therapists with experience in oral stimulation of preterm infants. The first guidance for parents has duration of approximately half an hour and then follow-up once or twice, depending on the needs of the family. To maintain consistent intervention over time is the program of oral stimulation written in a script, where the family also must record the following variables: date and time of oral stimulation. In occupational therapy the guidance and in the script examines the signs that the infant exhibits when it is ready / not ready for stimulation. The family also sees a movie where these signs and the program of oral stimulation review auditory and visual.
Study: NCT01043549

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: Repetitive transcranial stimulation of the posterior parietal cortex
Study: NCT01201785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: After having been on aspirin 81mg/daily for at least one-week, patients switched their aspirin regimen on a weekly basis according to the following scheme: aspirin 81mg twice daily (bid) for one week; aspirin 162 mg once daily (od) for one week; aspirin 162 mg bid for one week; aspirin 325 mg od for one week. Pharmacodynamic assessments were made after each sequence (5 time-points). Afterward, patients resumed the dose of aspirin that they were on prior to entering the study.
Study: NCT01043549

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Repetitive transcranial stimulation of the posterior parietal cortex
Study: NCT01191788

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Cognitive Behavioral Therapy
Description: 16 two hour sessions of group CBT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy
Description: 16 two hour sessions of group CBT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group CBT for Depression
Description: 16 of group CBT for depression delivered in 2 hour groups for up to 8 weeks by a trained substance abuse treatment counselor
Study: NCT03478501

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: This intervention is a tablet based Lethal Means Decision Aid with proposed use to augment lethal means counseling in emergency departments for patients at risk of suicide.
Study: NCT01959412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 27.5 mcg
Description: indacaterol 27.5 mcg twice daily inhaled once via inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 37.5
Description: Indacaterol 37.5 mcg once daily, inhaled once via inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 55 mcg
Description: Indacaterol 55 mcg once daily, inhaled once via inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 75 mcg
Description: Indacaterol 75 mcg once daily, inhaled once via inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 mcg
Description: Indacaterol 150 mcg once daily, inhaled once via inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to indacaterol once or twice daily (depending on assigned sequence) via inlaher

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to indacaterol once or twice daily (depending on assigned sequence) via inlaher

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to indacaterol once or twice daily (depending on assigned sequence) via inlaher

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to indacaterol once or twice daily (depending on assigned sequence) via inlaher

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to indacaterol once or twice daily (depending on assigned sequence) via inlaher
Study: NCT03018600

Intervention type: BEHAVIORAL
Intervention: diet and exercise intervention
Description: consult nutrious doctors giving specific food and take regular exercise when under steroid therapy
Study: NCT01959412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to indacaterol once or twice daily (depending on assigned sequence) via inlaher
Study: NCT03834753

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 1.25 mg, intravitreal injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: 0.5mg, intravitreal injection
Study: NCT01353092

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Re5 Pulsating ElectroMagnetic Fields
Description: Re5 Treatment Helmet using Pulsating ElectroMagnetic Fields (PEMF):~30 minutes of active PEMF therapy in the morning and 30 minutes of active PEMF therapy in the afternoon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Re5 Pulsating ElectroMagnetic Fields (PEMF)
Description: Re5 Treatment Helmet using Pulsating ElectroMagnetic Fields (PEMF):~30 minutes of sham therapy and 30 minutes of active therapy (morning or afternoon)
Study: NCT00295867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Zoledronic acid is a new, highly potent, heterocyclic nitrogen-containing third generation bisphosphonate that has demonstrated 40- to 850- fold greater potency than pamidronate in preclinical models of bone resorption. The mechanism of action of nitrogen-containing bisphosphonates such as pamidronate and zoledronic acid appears to involve inhibition of the mevalonate pathway
Study: NCT02225600

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40 IU Intranasal Oxytocin
Description: 40 IU intranasal oxytocin

Intervention type: DRUG
Group type: OTHER
Intervention: 40 IU Intranasal Oxytocin
Description: 40 IU intranasal oxytocin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Intranasal Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Intranasal Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 24 IU intranasal Oxytocin

Intervention type: DRUG
Group type: OTHER
Intervention: 24 IU intranasal Oxytocin
Study: NCT02271607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: moxibustion
Description: The treatment schedule is three times per week for four weeks. Indirect moxa pillars and indirect-container moxibustion will be used.
Study: NCT02642419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel)
Description: * Rivaroxaban will be orally administered after a meal at a dose of 15 mg if the creatinine clearance (CLcr) is 50 mL/min or more and at a dose of 10 mg if the CLcr is 15-49 mL/min (regardless of time)~* Antiplatelet will be selected from aspirin or thienopyridine derivatives (clopidogrel or prasugrel)~  * Aspirin will be orally administered once a day at a dose of 81 mg or 100 mg~ * Clopidogrel will be orally administered once a day after a meal at a dose of 75 mg. The dose will be reduced to 50mg once a day depending on age, body weight or clinical findings.~ * Prasugrel will be orally administered once a day at a dose of 3.75 mg. If the body weight is 50kg or less a reduced dose(2.5 mg once a day) will be considered depending on the age, renal function or other bleeding and thrombotic risk.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban will be orally administered at a dose of 15 mg if the creatinine clearance (CLcr) is 50 mL/min or more and at a dose of 10 mg if the CLcr is 15-49 mL/min.
Study: NCT01559506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air Barrier System device
Description: Device is deployed adjacent to the surgery site and activated.
Study: NCT03582956

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Euglycemic hyperinsulinemic clamp with tracer enhancement
Description: To characterize the impact of adiposity on metabolism during puberty, adolescents will undergo the euglycemic hyperinsulinemic clamp study with tracer enhancement.
Study: NCT03582956

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Euglycemic hyperinsulinemic clamp with tracer enhancement
Description: To characterize the impact of adiposity on metabolism during puberty, adolescents will undergo the euglycemic hyperinsulinemic clamp study with tracer enhancement.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Euglycemic hyperinsulinemic clamp with tracer enhancement
Description: A comparison control group of 36 lean young adults with T1D will also be enrolled, since they will be unaffected by the adverse metabolic effects of puberty or obesity.
Study: NCT03852433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bulevirtide
Description: Administered via subcutaneous injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bulevirtide
Description: Administered via subcutaneous injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bulevirtide
Description: Administered via subcutaneous injections
Study: NCT02929914

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local anesthesia and rubber dam isolation
Description: Local anesthesia was performed. Tooth was isolated using a rubber dam isolation in order to collect the dentin samples.
Study: NCT03852433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2a (PEG-IFN alfa)
Description: Administered via subcutaneous injections
Study: NCT01514123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VGX-100
Description: VGX-100 will be administered by IV infusion once every week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered by IV infusion once every 2 weeks
Study: NCT00660088

Intervention type: OTHER
Intervention: Ketasyn
Description: 10g for 7 days, 20g for 7 or 14 days

Intervention type: OTHER
Intervention: Ketasyn
Description: 10g for 7 days, 20g for 7 or 14 days

Intervention type: OTHER
Intervention: Ketasyn
Description: 10g for 7 days, 20g for 7 or 14 days

Intervention type: OTHER
Intervention: Ketasyn
Description: 10g for 7 days, 20g for 7 or 14 days

Intervention type: OTHER
Intervention: Ketasyn
Description: 10g for 7 days, 20g for 7 or 14 days
Study: NCT02929914

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local anesthesia and rubber dam isolation
Description: Local anesthesia was performed. Tooth was isolated using a rubber dam isolation in order to collect the dentin samples.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incomplete caries removal and microbiological samples collection
Description: Partial carious tissue was removed with conventional dentinal curette and collection of dentin with a spoon (1#) was performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incomplete caries removal and microbiological samples collection
Description: Partial carious tissue was removed with conventional dentinal curette and collection of dentin with a spoon (1#) was performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dentin washed with sodium 0.9% saline
Description: The remaining dentin was dipped in sodium 0.9% saline for 2min.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Antimicrobial Photodynamic Therapy
Description: The remaining dentin was disinfected with aPDT for 2 min.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microbiological samples collection and Indirect pulp treatment
Description: A new dentin collection was performed after this treatment at another site of the cavity. Then teeth were conventionally restored using the following materials: calcium hydroxide lining material and resin (Z350,3M).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microbiological samples collection and Indirect pulp treatment
Description: A new dentin collection was performed after this treatment at another site of the cavity. Then teeth were conventionally restored using the following materials: calcium hydroxide lining material and resin (Z350,3M).
Study: NCT01128842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: 240 mg once daily by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1500 mg/m\^2 twice daily by mouth.
Study: NCT01522508

Intervention type: PROCEDURE
Intervention: tetanic stimulation
Description: as test stimulus a painful tetanic stimulation is used

Intervention type: PROCEDURE
Intervention: tetanic stimulation
Description: as test stimulus a painful tetanic stimulation is used
Study: NCT01686828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyline
Description: 300 mcg/mL administered subcutaneously (at Day 0, Week 2)
Study: NCT00660088

Intervention type: OTHER
Intervention: Ketasyn
Description: 10g for 7 days, 20g for 7 or 14 days
Study: NCT00578838

Intervention type: OTHER
Intervention: Magnetic Resonance
Description: Patients each will undergo 4 MR examinations as part of this research study.
Study: NCT01321996

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 68Ga-DOTA-NOC PET/CT
Description: procedure: PET/CT scan with 68Ga-DOTA-NOC
Study: NCT02273154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: MDD patients with anxiety disorder take paroxetine (20-60mg/d), combining with buspirone (initial dose is 5mg tid, then increase the dose to 10mg tid on 4th day)
Study: NCT01686828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyline
Description: 300 mcg/mL administered subcutaneously (at Day 0, Week 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyline
Description: 300 mcg/mL administered subcutaneously (at Day 0, Week 2)
Study: NCT02273154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: MDD patients with anxiety disorder take paroxetine (20-60mg/d)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: MDD patients with anxiety disorder take paroxetine (20-60mg/d)
Study: NCT01686828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyline
Description: 300 mcg/mL administered subcutaneously (at Day 0, Week 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone 1.62% gel
Description: Transdermal Testosterone Gel (either 1.25g or 5g/d) for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone 1.62% gel
Description: Transdermal Testosterone Gel (either 1.25g or 5g/d) for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone 1.62% gel
Description: Transdermal Testosterone Gel (either 1.25g or 5g/d) for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole oral aromatase inhibitor 5mg daily for 4 weeks
Study: NCT01686828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo gel (for Testosterone 1.62% gel)
Description: placebo gel manufactured to mimic Testosterone 1.62% gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo pill (for Letrozole)
Description: Oral placebo aromatase inhibitor to mimic Letrozole 5mg/d
Study: NCT00006222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide
Study: NCT02184143

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBPT
Description: Changing Behavior through Physical Therapy (CBPT) is a cognitive-behavioral based self-management program.
Study: NCT00578838

Intervention type: OTHER
Intervention: Magnetic Resonance
Description: Patients each will undergo 4 MR examinations as part of this research study.

Intervention type: OTHER
Intervention: Magnetic Resonance
Description: You will have two MR exams on two different days. There will be no injection of contrast material. An MR exam requires about 1 hour. The second MR exam will take place 2-3 weeks after the first one. This second MR exam will take about 1 hour and will look at whether the results from the MR exams are reliable and repeatable.
Study: NCT03695055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance therapy post-HSCT
Description: Rituximab vs DPP/DCEP-G vs observation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance therapy post-HSCT
Description: Rituximab vs DPP/DCEP-G vs observation
Study: NCT00978887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retorna
Description: Dosage commensurate with surface to be treated, Retorna facial cream (Topical use), twice a day, for 4 weeks.
Study: NCT02184143

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Patient education
Study: NCT03782818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib up to 300 mg BID for 24 weeks
Study: NCT00748059

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standing or upright tilt
Description: stand upright or tilt table test

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microneurography
Description: Recording from sympathetic nerve

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QSweat
Description: quantitative sweat testing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neck cuff stimulation
Description: Blood pressure receptors in the neck arteries may be stimulated by applying suction through a collar around the neck.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenylephrine,isoproterenol,nitroprusside,propranolol,edrophonium,atropine,tyramine
Description: IV Pharmacological Testing~phenylephrine 12.5 - 400 ug, isoproterenol 0.1 - 0.4 ug or higher until desired effect, nitroprusside 0.1 - 1.6 ug/kg, propranolol 1.1 mg/min, edrophonium maximum of 10 mg, atropine .01 mg/kg, tyramine 250-4000 ug or higher until desired effect

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clonidine,yohimbine,metoclopramide,alpha-methyldopa
Description: Oral Pharmacological Testing~clonidine 0.1-0.3 mg, yohimbine 5-10 mg, metoclopramide 10 mg, alpha-methyldopa 62.5 mg, placebo

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BodPod
Description: Determination of body composition

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Eye exam
Description: Examination of pressure in the eye and eyelid fatiguability. The following eyedrops might be used:~1. 0.5% proparacaine (Alcaine, Allergan, Inc)~2. Fluress (0.4% benoxinate hydrochloride, fluorescein sodium, Akorn, Inc)~3. 0.5%, 1% tropicamide (Mydriacyl, Alcon)~4. Over-the-counter preservative-free artificial tears~5. 0.25%, 2.5% and 10% phenylephrine (Bausch and Lomb)~6. 1% cyclopentolate hydrochloride (Alcon)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleep study
Description: Recording of sleep pattern overnight

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pain response testing
Description: Subjects will rate the quality and intensity of 2 pain tasks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metabolic chamber
Description: Determination of metabolic rate via 24hr stay in whole-room indirect calorimeter

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain function studies
Description: Questionnaires and computer tasks, an EEG and an MRI may be used to assess brain function.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bicycle Exercise Test
Description: Blood pressure and heart rate may be monitored while exercising on a stationary bicycle.
Study: NCT02626819

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOVE! Toward Your Goals
Description: Patients will take an online tool accessing weight management and lifestyle behaviors, and will meet with a health coach regularly to establish SMART goals to help them in their weight loss journey. The goals may be supported by the patients' PACT members
Study: NCT00978887

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage commensurate with surface to be treated, Placebo facial cream (Topical use), twice a day, for 4 weeks
Study: NCT01686828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo pill (for Letrozole)
Description: Oral placebo aromatase inhibitor to mimic Letrozole 5mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo pill (for Letrozole)
Description: Oral placebo aromatase inhibitor to mimic Letrozole 5mg/d
Study: NCT02626819

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Patients will be given information on healthy living messages that were created by the VA, and given more information on specific messages they are interested in from the health coaches, but will not receive official coaching. These messages are the current standard of care at the VA for obesity counseling.
Study: NCT01995110

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-fat meal A

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-fat meal A

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-fat meal B